



The role of preprocedural mouth rinse application in decreasing COVID-19 transmission in Dental Care Settings: A mini-review

Sanaz Gholami Toghchi ¹, Nozhan Azimi ² and Nahal Azimi ^{3,*}

¹ Department of Oral and maxillofacial pathology, Dental school, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

² Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

³ International Campus, Tehran University of Medical Sciences, Tehran, Iran.

Open Access Research Journal of Biology and Pharmacy, 2022, 05(01), 001–006

Publication history: Received on 29 March 2022; revised on 04 May 2022; accepted on 06 May 2022

Article DOI: <https://doi.org/10.53022/oarjbp.2022.5.1.0040>

Abstract

The COVID-19 virus present in saliva and respiratory droplets is a possible high-risk source of viral transmission in health care settings. Dental practitioners and dentists in particular are highly susceptible to virus acquisition from their source patients. Mouthwashes before dental examination and procedures may be one possible solution to decrease the viral burden in the mouth, hence reducing transmission probability. Application of hydrogen peroxide, cetylpyridinium chloride, povidone-iodine, and chlorhexidine have been proposed to achieve this target. This paper aims to investigate for evidence in the literature for a decrease in the viral burden following preprocedural application of different mouthwashes.

Keywords: Covid-19; Mouthwash; Chlorhexidine; Cetylpyridinium chloride; Povidone-Iodine; Hydrogen peroxide

1. Introduction

Coronavirus Disease 2019 (COVID-19) particles are transmitted on a human-to-human basis via respiratory droplets and saliva [1]. These droplets may be generated during coughing, sneezing, talking, or simply by breathing [2]. Large respiratory droplets cannot remain suspended in the air long before settling on surfaces as far as 1 meter. The suspended droplets dry out and leave air-borne virus particles as a possible source of infectivity among individuals [2,3].

Manifestations of COVID-19 are diverse among individuals. The most prevalent symptoms are pyrexia, breathing difficulties, coughing, and fatigue. Neurological manifestations such as loss of smell or dermatological symptoms such as rashes or hives are also common among patients [4,5]. Several patients have experienced oral manifestations including vesiculobullous lesions and ulcers most commonly seen in the tongue, labial or buccal mucosa, and the palate [5,6]. Moreover, the COVID-19 pandemic has had a negative impact on the mental well-being of the population and it may have raised the stress and depression level among individuals [7]. Therefore, it is imperative to end the pandemic as soon as possible.

Vaccines play an essential role in terminating the coronavirus-2 pandemic. They are produced based on either conventional approaches like inactivated vaccines or they may be generated based on more novel platforms like RNA vaccines [8,9]. Additionally, other preventive strategies such as social distancing, hand washing, and wearing masks should be considered in order to decrease COVID-19 transmission [10].

* Corresponding author: Nahal Azimi
International Campus, Tehran University of Medical Sciences, Tehran, Iran.

In dental settings, in particular, the performance of different dental procedures plays an additional role in this human-to-human transmission. Ultrasonic scalers and slow and high-speed handpieces are dental equipment that spatter aerosol and can transmit the virus [11]. The contaminated or unclean dental aerosol can be associated with the transmission of SARS-CoV-2 in the dental setting via direct or indirect contact [3].

Several researchers have suggested a set of safety measures for dental professionals, including the use of preprocedural mouth rinses by both patients and dental clinic staff [3]. Oral rinses decline the microbial load of the oral cavity therefore; they may be useful in decreasing the transmission of pathogens in a dental office [11]. A number of studies have suggested that mouth rinses have an antiviral role against SARS-CoV-2. However, more studies are warranted regarding their efficacy in COVID-19 viral load depletion in dental settings [3].

2. Discussion

The unknown and heritable mutations of coronavirus-2 are still a threat to developing countries. Respiratory hygiene and oral hygiene are crucial countermeasures in the battle against COVID-19 [12]. Many health care organizations suggested a set of countermeasures, including the use of preprocedural mouthwashes to decrease the risk of cross-infection and carrying COVID-19 infection among health professionals [13]. The American Dental Association (ADA) has proposed 2 categories of mouth rinses: cosmetic and therapeutic. Cosmetic mouthwashes are used to control bad breath temporarily but do not have any biological or chemical effects. On the other hand, therapeutic mouth rinses have active ingredients that are clinically effective in controlling or treating conditions such as plaque, halitosis, and gingivitis [14].

Various clinical evidence is presently associated with the antiviral action of mouth rinses and the main mechanism of action is most likely through the destruction of virus envelopes [15]. A number of studies have reported the effectiveness of different mouth rinses against COVID-19 [3]. A study assessed the antiviral effect of 8 commercially available mouth rinses on SARS-CoV-2 and concluded that 1. dequalinium chloride and benzalkonium chloride active components, as well as 2. 1% Povidone-Iodine (PI), and 3. ethanol combined with essential oils, markedly decrease the virus infectivity [16]. A recent in-vitro study showed that mouthwashes with cetylpyridinium chloride (CPC) significantly drop the infectivity of different variants of SARS-CoV-2 and can decline the transmission among infected patients regardless of the variant [17]. A recent study determined the virucidal activity of PI and found that it can inactivate SARS-CoV-2 at the minimum concentration of 0.5 %. The results support the utilization of PI preprocedural mouth rinse for patients to avoid transmission of COVID-19 in dental settings [18]. A clinical study assessed the effect of chlorhexidine (CHX) mouthwash on the viral load and showed that 0.12% CHX was effective in lowering the SARS-CoV-2 viral load for 2 hours [19].

Oral rinse application prior to dental visit is recommended since it may decrease the viral burden present in oropharyngeal tissues. However, more studies are warranted to determine the ability of mouthwashes for the total elimination of the viral load. There is also an explicit need for a detailed analysis of the effectivity of various mouth rinses against COVID-19 during dental care [3].

2.1. Chlorhexidine (CHX)

CHX is the most commonly used oral antiseptic agent in dentistry. It is a broad-spectrum disinfectant with long-lasting activity against bacteria and can be prescribed to decrease dental plaque accumulation, and treat gingivitis and periodontitis [20]. Though several side effects have been described for CHX mouthwash, it is considered a safe agent. The most prominent adverse reactions of CHX are xerostomia, taste alterations, and tooth staining or discoloration [21].

A study evaluated the antiviral effectiveness of 0.12% CHX by applying virucidal assays in tissue cultures and suggested that it is effective against a variety of lipid-enveloped viruses such as cytomegalovirus influenza A, parainfluenza, hepatitis B, and herpes simplex virus in only 30 seconds. However, the viruses respond differently to CHX due to minor differences in the physicochemical properties of their envelopes [22]. Another study has shown the possible effect of CHX against the contaminants present on various inanimate surfaces such as metal, glass, or plastic and has observed that CHX is less effective against coronavirus compared to other compounds such as ethanol and hydrogen peroxide (HP) [23]. Nevertheless, these findings cannot be extended to the oral cavity.

An *in vitro* study assessed the antiviral effect of CHX and PI against COVID-19 and demonstrated that while both agents are effective against the virus, 0.2% CHX causes inactivation of 99.9% the virus in a short time duration of 30 seconds and acts stronger than 1% PI [24].

A recent clinical study on 2 COVID-19 positive patients has shown that CHX mouthwash (0.12%, 15 mL) reduces the viral load of SARS-CoV-2 for almost 2 hours, which can prevent the transmission of the virus in the dental setting. However, the study indicates a number of limitations such as a small sample size and recommends further large-scale studies to find out the effectiveness of the CHX mouth rinse in reducing the transmission of COVID-19 [19].

2.2. Cetylpyridinium chloride (CPC)

CPC is a quaternary ammonium, soluble in both water and alcohol. It is considered a safe and effective antimicrobial mouth rinse frequently used to control gingivitis and periodontitis [3,25]. Long-term usage of mouthwashes containing CPC may result in oral paresthesia, calculus formation, and tooth discoloration. However, their temporary or short-term application does not typically result in tooth stain formation [23].

A randomized clinical trial suggested that CPC mouth spray is effective in reducing the duration and severity of manifestations of viral upper airways infections. The researchers stated that the spray works by providing a barrier between the host mucous membrane and the virus and its CPC component destructs the lipid envelope of viruses [26].

A study on COVID-19 virus-like particles demonstrated that the application of CPC in concentrations above 0.05% leads to a disruption in the particles however, no significant effect was observed in lower concentrations of the agent [27]. Another *in vitro* study stated that 0.075% CPC combined with 0.05% sodium fluoride has efficient antiviral activity against COVID-19 in only 30 seconds [28].

2.3. Povidone-Iodine (PI)

PI acts against bacteria, fungi, viruses, and spores. The agent affects viruses with lipid envelopes more efficiently than non-lipid enveloped viruses. It is assumed that PI influences the proteins present on the surface of enveloped viruses and also reacts with the fatty acids of the membranes [3]. Transient burning sensation, mild itching, irritation, and discoloration are major side effects of using PI and it is contraindicated in individuals with thyroid or renal disorders, or pregnant women [3,29].

A study tested PI oral rinse in a concentration of 0.23% on SARS-CoV and MERS-CoV in a 15-second time duration and observed that it exerts antiviral activity. The researchers suggested that it could be an effective and preventive measure for people more susceptible to respiratory or oral infections [30]. PI is also a crucial compound effective against coronavirus-2 [3]. An *in vitro* study evaluated the effectiveness of mouth rinses containing PI in different concentrations and demonstrated that even the lowest dose applied (0.5%) leads to a reduction in SARS-CoV-2 viral burden in 15 seconds [18]. This was in line with another study concluding that 0.5% PI causes inactivation of the virus in a 15-second time duration [31].

A study on 4 patients with SARS-CoV-2 infection revealed that 1% PI mouthwash administered for 1 minute can be effective in the reduction of saliva viral load in patients with a higher viral burden. The researchers recommended that the oral rinse could be useful for symptomatic COVID-19 patients, particularly during the first week of their symptoms, when greatest viral changes occur in the saliva. However, the study suggested further clinical studies to confirm the results [32]. In another clinical study on 315 patients undergoing nasopharyngeal endoscopies, they were asked to use PI oral rinses and nasal drops. The researchers stated that since PI mouthwash and nasal drops are safe agents, the protocol may be effective in controlling the COVID-19 viral burden and preventing transmission of the virus among healthcare workers and patients [33].

2.4. Hydrogen peroxide (HP)

HP is a powerful oxidizing agent readily available to consumers in different concentrations. Due to its broad-spectrum antimicrobial role, it may be used for disinfection and sterilization purposes [3]. HP works by generating oxygen-free radicals, which disrupt various parts of the cell, including its lipid membrane. While HP may cause toxicity at concentrations above 5%, its usual concentration as an oral rinse (1–3%) causes no harm [34].

An *in vitro* study compared HP to PI regarding inactivation of COVID-19 and observed that HP in 1.5% and 3% doses has minute antiviral activity against SARS-CoV-2 even after 30 seconds of exposure. However, PI in concentrations of 0.5% to 1.5% leads to complete inactivation of the virus in only 15 seconds [35]. Another study comparing various oral rinses together, also found HP's virucidal role less effective than PI [16].

In a clinical study on patients attending a dental clinic, the researchers placed HEPA filters in the waiting room and the therapy rooms. In the waiting room, patients had not used gargles but they wore masks while in the treatment rooms,

they were asked to use a 1% HP for 1 minute and to take off their masks. The researchers observed the COVID-19 viral burden only in the waiting room and stated that HP mouthwash might decrease the viral transmission significantly during aerosol-producing dental procedures [36]. Another study conducted on ten individuals with COVID-19 showed that using 1% HP oral rinse for 30 seconds does not have a beneficial effect on the reduction of the SARS-CoV-2 viral load and suggested further studies on other possible preprocedural agents [37].

3. Conclusion

Use of preprocedural mouth rinses may reduce the viral load of SARS-CoV-2 in saliva and the oral cavity, thus it may be helpful to decrease the chance of transmission of the virus from person-to-person contact in dental offices. There may be less chance of viral transmission in dental clinics if the patients and dental practitioners use preprocedural mouth rinses. Nevertheless, more *in vivo* and clinical studies are warranted to prove the efficacy of mouthwashes against COVID-19.

Compliance with ethical standards

Acknowledgments

Authors like to thank Dr. Mahmood Dashti for his help during writing this article.

Disclosure of conflict of interest

All of the authors have read this manuscript, and there are no conflict of interest.

References

- [1] World Health Organization (2020). Transmission of SARS-CoV-2: implications for infection prevention precautions: scientific brief, 09 July 2020. World Health Organization; 2020.
- [2] Vinayachandran D, Balasubramanian S. Salivary diagnostics in COVID-19: Future research implications. *J Dent Sci.* 2020 Sep;15(3):364–6.
- [3] Reis INR, do Amaral GCLS, Mendoza AAH, das Graças YT, Mendes-Correa MC, Romito GA, et al. Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols? *Med Hypotheses.* 2021 Jan;146:110436.
- [4] da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien Klin Wochenschr.* 2021 Apr;133(7–8):377–82.
- [5] Baban B, Stevens MR, Ghasemi S, Boojar FMA, Dashti M. New manifestation of Covid-19 in oral region, a potential faster diagnosis approach, a mini review. *J Dent Oral Epidemiol.* 2021;1(1).
- [6] Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: A review article. *Dermatol Ther.* 2021 Jan;34(1):e14578.
- [7] Sabouhi S, Vaezi A, Sharbafchi M, Aerni A, Bentz D, Coynel D, et al. The Iranian Corona Stress Study. 2020.
- [8] Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. *BMC Med [Internet].* 2021;19(1):173. Available from: <https://doi.org/10.1186/s12916-021-02059-5>
- [9] Ghasemi S, Dashti M. Fight against COVID-19 with mRNA vaccines and interaction with Dermal fillers. *Clin Exp Vaccine Res.* 2021 May;10(2):151–3.
- [10] McIntosh K, Hirsch MS, Bloom A. COVID-19: Epidemiology, virology, and prevention. UpToDate Available online: <https://www.uptodate.com/contents/covid-19-epidemiology-virology-andprevention> Accessed. 2021;18.
- [11] Marui VC, Souto MLS, Rovai ES, Romito GA, Chambrone L, Pannuti CM. Efficacy of preprocedural mouthrinses in the reduction of microorganisms in aerosol: A systematic review. *J Am Dent Assoc.* 2019 Dec;150(12):1015–1026.e1.
- [12] Shohreh Ghasemi, Mahmood Dashti. New Unknown Sars-Cov-2 Virus Variants and Hidden Pandemics Within Them in Developing Countries, 21 September 2021, PREPRINT (Version 1) available at Research Square [<https://doi.org/10.21203/rs.3.rs-898454/v1>]

- [13] Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. *Int J Oral Sci* [Internet]. 2020;12(1):9. Available from: <https://doi.org/10.1038/s41368-020-0075-9>
- [14] No Title Mouthrinse (Mouthwash) [Internet]. Department of Scientific Information, Evidence Synthesis & Translation Research, ADA Science & Research Institute, LLC. 2021. Available from: <https://www.ada.org/resources/research/science-and-research-institute/oral-health-topics/mouthrinse-mouthwash>
- [15] Chen M-H, Chang P-C. The effectiveness of mouthwash against SARS-CoV-2 infection: A review of scientific and clinical evidence. *J Formos Med Assoc.* 2021 Oct;121(5):879–85.
- [16] Meister TL, Brüggemann Y, Todt D, Conzelmann C, Müller JA, Groß R, et al. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2. *J Infect Dis.* 2020 Sep;222(8):1289–92.
- [17] Muñoz-Basagoiti J, Perez-Zsolt D, León R, Blanc V, Raïch-Regué D, Cano-Sarabia M, et al. Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. *J Dent Res* [Internet]. 2021 Jul 20;100(11):1265–72. Available from: <https://doi.org/10.1177/00220345211029269>
- [18] Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. *J Prosthodont Off J Am Coll Prosthodont.* 2020 Jul;29(6):529–33.
- [19] Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, et al. Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. *J Korean Med Sci.* 2020 May;35(20):e195.
- [20] Ghasemi S, Dashti M. Using mouthwashes by a healthcare practitioner in order to decrease the chance of transmission of covid-19. *J Dent Oral Disord.* 2021;7(3).
- [21] Brookes ZLS, Bescos R, Belfield LA, Ali K, Roberts A. Current uses of chlorhexidine for management of oral disease: a narrative review. *J Dent.* 2020 Dec;103:103497.
- [22] Bernstein D, Schiff G, Echler G, Prince A, Feller M, Briner W. In vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate mouthrinse. *J Dent Res.* 1990 Mar;69(3):874–6.
- [23] Tartaglia GM, Tadakamadla SK, Connelly ST, Sforza C, Martín C. Adverse events associated with home use of mouthrinses: a systematic review. *Ther Adv drug Saf.* 2019;10:2042098619854881.
- [24] Jain A, Grover V, Singh C, Sharma A, Das DK, Singh P, et al. Chlorhexidine: An effective anticovid mouth rinse. *J Indian Soc Periodontol.* 2021;25(1):86–8.
- [25] Teng F, He T, Huang S, Bo C-P, Li Z, Chang J-L, et al. Cetylpyridinium chloride mouth rinses alleviate experimental gingivitis by inhibiting dental plaque maturation. *Int J Oral Sci.* 2016 Sep;8(3):182–90.
- [26] Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA, et al. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. *BMC Infect Dis.* 2017 Jan;17(1):74.
- [27] Bañó-Polo M, Martínez-Gil L, Sánchez del Pino MM, Massoli A, Mingarro I, León R, et al. Cetylpyridinium chloride promotes disaggregation of SARS-CoV-2 virus-like particles. *J Oral Microbiol* [Internet]. 2022 Dec 31;14(1):2030094. Available from: <https://doi.org/10.1080/20002297.2022.2030094>
- [28] Tiong V, Hassandarvish P, Bakar SA, Mohamed NA, Wan Sulaiman WS, Baharom N, et al. The effectiveness of various gargle formulations and salt water against SARS-CoV-2. *Sci Rep* [Internet]. 2021;11(1):20502. Available from: <https://doi.org/10.1038/s41598-021-99866-w>
- [29] McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. *Clin Microbiol Rev.* 1999 Jan;12(1):147–79.
- [30] Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. *Infect Dis Ther.* 2018 Jun;7(2):249–59.
- [31] Shet M, Westover J, Hong R, Igo D, Cataldo M, Bhaskar S. In vitro inactivation of SARS-CoV-2 using a povidone-iodine oral rinse. *BMC Oral Health* [Internet]. 2022;22(1):47. Available from: <https://doi.org/10.1186/s12903-022-02082-9>
- [32] Martínez Lamas L, Diz Dios P, Pérez Rodríguez MT, Del Campo Pérez V, Cabrera Alvargonzalez JJ, López Domínguez AM, et al. Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. *Oral Dis.* 2022 Apr;28 Suppl 1:908–11.

- [33] Khan MM, Parab SR, Paranjape M. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. *Am J Otolaryngol*. 2020;41(5):102618.
- [34] O'Donnell VB, Thomas D, Stanton R, Maillard J-Y, Murphy RC, Jones SA, et al. Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. *Function* [Internet]. 2020 Jan 1;1(1):zqaa002. Available from: <https://doi.org/10.1093/function/zqaa002>
- [35] Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses. *J Prosthodont Off J Am Coll Prosthodont*. 2020 Aug;29(7):599–603.
- [36] Burgos-Ramos E, Urbietta IR, Rodríguez D. Is hydrogen peroxide an effective mouthwash for reducing the viral load of SARS-CoV-2 in dental clinics? *Saudi Dent J* [Internet]. 2022;34(3):237–42. Available from:
- [37] Gottsauner MJ, Michaelides I, Schmidt B, Scholz KJ, Buchalla W, Widbiller M, et al. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. *Clin Oral Investig*. 2020 Oct;24(10):3707–13.